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Abstract
Background: Understanding the discrepancy between IgE sensitization and allergic 
reactions to peanut could facilitate diagnosis and lead to novel means of treating 
peanut allergy.
Objective: To identify differences in IgE and IgG4 binding to peanut peptides be-
tween peanut-allergic (PA) and peanut-sensitized but tolerant (PS) children.
Methods: PA (n = 56), PS (n = 42) and nonsensitized nonallergic (NA, n = 10) patients 
were studied. Synthetic overlapping 15-mer peptides of peanut allergens (Ara h 1-11) 
were spotted onto microarray slides, and patients’ samples were tested for IgE and 
IgG4 binding using immunofluorescence. IgE and IgG4 levels to selected peptides were 
quantified using ImmunoCAP. Diagnostic model comparisons were performed using 
likelihood-ratio tests between each specified nominal logistic regression models.
Results: Seven peptides on Ara h 1, Ara h 2, and Ara h 3 were bound more by IgE of 
PA compared to PS patients on the microarray. IgE binding to one peptide on Ara h 5 
and IgG4 binding to one Ara h 9 peptide were greater in PS than in PA patients. Using 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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1  | INTRODUC TION
Allergen-specific IgE is necessary but not sufficient for the devel-
opment of allergic reactions to a food allergen. Thus, IgE sensi-
tization to foods can often be identified without proven clinical 
relevance. For instance, in the case of peanut, about 11.8% of 
school-age children in the United Kingdom have detectable spe-
cific IgE to peanut and only 2.6% are actually peanut-allergic as 
confirmed by double-blind placebo-controlled food-challenge 
(DBPCFC).1 This discrepancy between allergic sensitization and 
clinical reactivity poses diagnostic difficulties and raises funda-
mental questions about the mechanisms of food allergy and oral 
tolerance. If IgE binds to the allergen in immunoassays to peanut, 
why is it not able to cause effector cell activation in the majority 
of patients?
We have been addressing two nonmutually exclusive hypotheses 
to explain the discrepancy between the presence of peanut-specific 
IgE (P-sIgE) and peanut allergy. The first hypothesis is that there may 
be differences in the characteristics of allergen-specific IgE between 
peanut-allergic (PA) and peanut-sensitized but tolerant (PS) patients. 
We have previously shown that, at the population level, PA patients 
tend to have higher levels of P-sIgE and to have IgE directed to the 
major peanut allergens, Ara h 1, Ara h 2, and Ara h 3.2 However, there 
is a large overlap in the distribution of specific IgE levels in PA and 
PS patients. At the individual level, many cases can be found of PS 
patients who eat peanut without developing any symptoms and have 
relatively higher levels of P-sIgE compared with PA patients who de-
velop allergic reactions, often severe, when exposed to peanut. This 
is also the case when considering specific IgE to Ara h 2, which has 
proved to be particularly discriminative between allergic and tolerant 
ImmunoCAP, IgE to the Ara h 2 peptides enhanced the diagnostic accuracy of Ara h 
2-specific IgE. Ratios of IgG4/IgE to 4 out of the 7 peptides were higher in PS than in 
PA subjects.
Conclusions: Ara h 2 peptide-specific IgE added diagnostic value to Ara h 2-specific 
IgE. Ability of peptide-specific IgG4 to surmount their IgE counterpart seems to be 
important in established peanut tolerance.
K E Y W O R D S
Ara h 2, diagnosis, epitopes, food allergy peanut allergy
G R A P H I C A L  A B S T R A C T
This study identifies differences in IgE and IgG4 binding to peanut peptides between peanut-allergic and peanut-sensitized children. Peanut 
peptide microarray analyses reveal that seven peptides on Ara h 1, Ara h 2 and Ara h 3 are bound more by IgE of peanut-allergic compared 
to peanut-sensitized patients. Measuring IgE to the Ara h 2 peptides in combination with Ara h2 enhances the diagnostic accuracy of Ara h 
2-specific IgE.
Abbreviation: PPV, positive predictive value
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individuals.3 Refining IgE specificity at the epitope level may clarify 
this further; with existing experimental approaches using microarray 
and other platforms allowing to primarily identify linear epitopes.4-7 
Various groups have studied IgE epitopes on peanut allergens; how-
ever, most studies focused on searching for peanut epitopes bound 
by IgE of peanut-allergic patients and were limited to Ara h 2 or at 
most Ara h 1, Ara h 2, and Ara h 3. Ours was the first study to test 
IgE and IgG4 binding to all peanut allergens and to analyze the dif-
ferential binding between PA and PS who were mostly sensitized to 
peanut major allergens, some able to cause allergic symptoms (as in 
the case of PA patients) and some not (as in the case of PS subjects).
The second hypothesis to explain the discrepancy between sen-
sitization and allergy is that PS patients may have a peanut-specific 
antibody, such as IgG4, that are able to interfere with the allergen-IgE 
interaction. We previously showed that the levels of IgG4 to peanut 
were higher in PS compared with PA patients but it was the relative 
amount of IgG4 compared with IgE in individual patients, that is, the 
IgG4/IgE ratio, that enabled a clearer distinction between PA and PS 
patients with PS patients having higher IgG4/IgE ratios for peanut, 
Ara h 1, Ara h 2, and Ara h 3.2 Depletion of IgG4 antibodies from 
plasma samples with detectable IgE to the major peanut allergens 
that would otherwise be predictive of peanut allergy partially re-
stored mast cell activation, which supported a role of IgG4 in the ab-
sence of an effector cell response characteristic of peanut tolerance.2
A complete understanding of the mechanisms by which IgE and 
allergen may or may not be able to elicit effector cell activation that 
is responsible for the clinical manifestations of allergic disease re-
quires a molecular approach. In this study, we aimed to identify the 
epitope specificities of IgE and IgG4 in PA and PS children to improve 
our understanding of the interplay between IgE and IgG4 in mod-




Patients undergoing diagnostic evaluation for suspected peanut 
allergy were studied. The study was approved by the South East 
London 2 Research Ethics Committee. Written informed consent 
was obtained from the parents of all participants. Study partici-
pants underwent detailed clinical assessment, skin prick testing, 
specific IgE and IgG4 testing, and oral peanut challenges, as previ-
ously described.8 Skin prick testing was performed using a commer-
cially available peanut extract (ALK-Abelló). Serum-specific IgE and 
IgG4 to peanut were measured using an immunoenzymatic assay 
(ImmunoCAP, Thermo Fisher). Specific IgE to 112 allergens was de-
termined using the ISAC microarray (Thermo Fisher).
Study participants were grouped as PA, PS and nonsensitized 
nonallergic (NA). Peanut allergy was confirmed by a positive oral 
food challenge (OFC) or by the combination of reported immedi-
ate-type allergic reactions to peanut and skin prick test (SPT) and/
or P-sIgE greater or equal than the validated 95% positive predic-
tive value (PPV) cutoffs of 8 mm and 15 kU/L, respectively. Peanut 
allergy was excluded by a negative OFC or the ability to eat ≥ 4 g 
of peanut protein twice a week, as assessed by a validated peanut 
consumption questionnaire. Peanut-sensitization was defined by a 
wheal size of peanut SPT ≥ 1 mm and/or specific IgE ≥ 0.10 KUA/L. 
Out of the 108 patients studied, 78 (72%) had OFC, 68 had DBPCFC, 
and 10 had open OFC for logistical reasons, as previously reported. 
Twelve (15%) of OFC were positive, and 66 (85%) were negative.
2.2 | Peanut peptide microarray
Synthetic overlapping 15-mer peptides representing the entire 
amino acid sequence of ten peanut allergens Ara h 1 to 11 (Table S1), 
offset by 5 amino acids, were synthesized and printed in triplicate 
onto microarray slides (JPT Peptide Technologies GmbH, Berlin, 
Germany) together with peptides from other nuts and plant foods 
(see Table S2 for a full list of the peptides tested). Slides were 
placed in individual chambers of a HS400 ProTM (Tecan, San Jose, 
CA) and blocked in filtered Superblock (Thermo, Rockford, IL) for 
30 minutes at room temperature (RT). Following a wash with tris-
buffered saline containing Tween-20, patients’ plasma was injected 
and incubated at 4°C overnight. Slides were sequentially washed 
and incubated with mouse anti-human IgE and Cy3-conjugated goat 
anti-mouse IgG (both Life Technologies, Grand Island, NY). Slides 
were scanned using GenePix-4000B and the software GenePix-
Pro7. The same slide was then re-blocked with Superblock and se-
quentially washed as above and incubated with rabbit-anti-human 
IgG4 (Abcam, Cambridge, MA) and anti-rabbit IgG Alexa Fluor (Life 
Technologies, Grand Island, NY) at RT for 30 minutes. The slides 
were washed and dried before scanning as above. IgE binding was 
measured by the Cy3, green fluorescence at 532 nm, and IgG4 bind-
ing by Alexa Fluor red fluorescence at 635 nm wavelength.
2.3 | Microarray data analysis
Scanning slides with GenePix Pro 7 (GP7) software-generated multi-
layer TIFF files which were analyzed by GP7 to generate GPR data 
files. These were read into the statistical software environment R, 
where all statistical analyses were done.9 Quality assessment, pre-
processing and differential binding analysis of the microarray data 
were performed using tools included in the limma package10 avail-
able through the Bioconductor project.11 Preprocessing of data 
comprised log-subtraction of mean background for each probe, 
mean-summarization of replicate probes followed by single-channel 
quantile normalization between arrays for contrasts involving only 
one antibody, and probe-level two-channel loess-normalization 
within arrays before computing IgG4/IgE ratios. IgE and IgG4 bind-
ing was expressed as the base 2 logarithm of the foreground to back-
ground ratio (FBR). See methods’ section of the online repository for 
more details.
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2.4 | Identification of the epitopes in the 3D 
structure of the allergens
The locations of the peptides in the 3D structures of the allergens, 
as deposited in the RCSB Protein Data Bank, were identified and 
visualized using PyMOL.12
2.5 | Quantification of specific IgE and IgG4 
to peptides
Unblocked peptides (JPT Peptide Technologies GmbH, Berlin, 
Germany) were conjugated to the solid phase of ImmunoCAP by 
Thermo Fisher (Uppsala, Sweden). IgE and IgG4 binding was quan-
tified using the Phadia 100 following the manufacturer's instruc-
tions. IgG4/IgE ratios were calculated as previously described by 
converting IgG4 levels from milligrams per liter to nanograms per 
milliliter and the peanut-specific IgE levels from kilo unit per liter 
to nanograms per milliliter with the use of the formula log10((IgG4 
× 1000) ÷ (IgE × 2.4)).2,13 Diagnostic model comparisons were per-
formed using likelihood-ratio tests between each specified nominal 
logistic regression models using SAS version 9.4 and JMP Pro 14.
3  | RESULTS
3.1 | Study population
Plasma samples of patients consecutively and prospectively recruited 
were tested on a peanut peptide allergen microarray. Demographic 
and clinical data can be found in Table S3. Most patients were sensi-
tized to the three major peanut allergens Ara h 1-3 (Table S4). Data 
of the 89 patients for whom there were results for both IgE and IgG4 
binding following appropriate quality control (53 PA, 27 PS and 9 NA) 
were analyzed and compared between PA and PS patients. Total IgE 
(P = .402) and peanut-specific IgG4 (P = .122) were not significantly 
different between the 2 groups. PA patients had higher sIgE to pea-
nut, (P < .001), Ara h 1 (P = .007), Ara h 2 (P < .001), and Ara h 3 
(P = .017) than PS patients. Forty-six percent of patients assessed on 
ISAC were sensitized to Ara h 6 (84% of PA and 10% of PS) and 22% 
were sensitized to profilins (18% of PA and 33% of PS) with 13% being 
sensitized to Phl p 12 (6% of PA and 25% of PS)—data not shown.
3.2 | Ara h 1, Ara h 2, and Ara h 3 peptides were 
differentially bound by IgE of peanut-allergic and 
peanut-sensitized but tolerant patients
Various peanut peptides were able to bind IgE of peanut-sensitized 
patients, including both PA and PS patients (Figure S1). When ana-
lyzing the differences between PA and PS patients, 7 peptides as-
sociated with the major peanut allergens Ara h 1, Ara h 2, and Ara 
h 3 emerged in the differential binding analyses as having a higher 
degree of IgE binding in PA compared with PS patients (Figure 1, 
Table 1, and Figure S2). Peptide 10, on Ara h 5 (AA51-65) was bound 
preferentially by IgE of PS than by IgE of PA patients (Table 1). There 
was a positive association between IgE to the Ara h 5 peptide and 
IgE to peptides from Ara h 8 (Table S5). IgE binding to peptides from 
other peanut allergens was not significantly different between PA 
and PS patients.
3.3 | All peptides identified on Ara h 1, 
Ara h 2, and Ara h 3 were located on the 
surface of the allergens and thus were susceptible to 
antibody binding
The identified Ara h 1, Ara h 2, and Ara h 3 peptides were located 
on the surface of the allergens in structurally disordered or partially 
disordered loop regions (Figure 2). The Ara h 1 peptides (peptides 7 
and 8) overlapped by 10 amino acids, ranging between amino acid 
85 and 105 of the allergen, and were located in a part of the pro-
tein that is absent from the crystal structure and was predicted as 
disordered. Two of the Ara h 2 peptides, peptide 1 (AA61-75) and 
peptide 3 (AA81-95) were located on a flexible loop in a partially 
disordered region. The other two overlapping Ara h 2 peptides, pep-
tide 2 (AA26-40) and peptide 4 (AA31-45), consisted of parts of two 
helices linked by a loop, located in the N-terminal region close to the 
link to maltose-binding protein (MBP) with which Ara h 2 was ex-
pressed and crystallized as a fusion protein.14 The peptide identified 
in Ara h 3, peptide 9 (AA324-338) was located on a loop of a partially 
disordered region in an exposed part of the protein crystal structure.
3.4 | Quantification and diagnostic utility of IgE 
to the 7 peptides using ImmunoCAP
In order to validate our findings, we quantified IgE levels using the 
ImmunoCAP technology to the 7 peanut peptides that were bound 
more by IgE of PA than by IgE of PS on the microarray (Figure 3 and 
Figure S3). The differences in IgE binding to the peanut peptides be-
tween PA and PS patients were independent of their peanut-specific 
IgE levels (Figure S4). Specific IgE to the individual allergen compo-
nents was detectable both in PA and in PS subjects (Table S3) and 
was generally related to specific IgE to the peptides from the respec-
tive allergen in both PA and PS subjects (Figures S5 and S6).
Considering the utility of ImmunoCAP to peptides to discrimi-
nate between peanut-allergic and nonallergic subjects among sen-
sitized individuals, specific IgE to the four Ara h 2 peptides showed 
good diagnostic discrimination and enhanced the accuracy of Ara h 
2-specific IgE (Figure 4). Specific IgE to peptides from Ara h 1 or Ara 
h 3 did not offer advantage over the respective allergen-specific IgE 
(Figures S7 and S8). Specific IgE to peanut was inferior to specific IgE 
to Ara h 2 (Figure S9).
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3.5 | Similarity of IgE and IgG4 binding to 
peanut peptides
On the microarray, IgG4 binding to one Ara h 9 peptide, to one pep-
tide from another lipid-transfer protein from peach Pru p 3 and from 
Gly m 5 from soya was greater in PS than in PA patients (Figure 1B, 
Table 1). For the remaining allergen peptides, there were no statisti-
cally significant differences in IgG4 binding between the two groups 
of patients. Overall, there was a strong association between peanut 
peptides bound by IgG4 and IgE both in PA and PS patients (Figure 
S10A). The number of peanut peptides bound by IgG4 and IgE was 
similar between the two groups of patients (Figure S10B); however, 
F I G U R E  1   Volcano plots for (A) IgE and (B) IgG4 binding to peanut peptides between peanut-allergic (PA) and peanut-sensitized 
tolerant (PS) patients. The x-axis represents the log2 fold changes of average foreground-to-background ratio between PA and PS patients. 
The y-axis represents the empirical Bayes log-odds (B) of differential binding between PS and PA. Peanut peptides (blue dots) that are 
differentially bound between the groups (B > 0, ie, odds of differential binding higher than those of no effect, with FDR < 0.05) are named in 
the figure. (C) Heat map of IgE binding to peptides significantly more bound in PA (in red) than PS (in green) patients (NA patients are shown 
in grey for comparison) expressed as the binary logarithm of foreground-to-background ratio (log2(FBR))
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overall the ratio of IgG4/IgE to peanut peptides was higher in PS 
than in PA patients (Figure S11).
Using ImmunoCAP, we were able to quantify the levels of anti-
bodies directed to specific peptides and to calculate with precision 
the relative amounts of IgE and IgG4. IgG4 levels to any of the 7 pep-
tides were not significantly different between PA and PS. IgG4/IgE 
ratios were higher in PS than in PA patients for antibodies directed 
to peptides 1, 3, and 4 of Ara h 2, as well as to peptide 9 of Ara h 3 
(Figure 5). Interestingly, we observed correlation of peptide-specific 
IgE and IgG4 with age (Figure S12).
4  | DISCUSSION
The discrepancy between the presence of P-sIgE and IgE-mediated 
allergic reactions to peanut is intriguing in that patients with simi-
lar levels of P-sIgE and even Ara h 2-specific IgE can have different 
clinical outcomes, some being PA and some being able to eat peanut 
without developing any symptoms. To explore the underlying rea-
sons for this discrepancy, we have tested PA and PS patients for IgE 
and IgG4 binding to 15-mer peptides covering the sequence of all 
peanut allergens known at the time when the microarray was gener-
ated. We identified four Ara h 2 peptides, two Ara h 1 peptides and 
one Ara h 3 peptide that were bound preferentially by IgE of PA than 
by IgE of PS. One peptide of the profilin Ara h 5 was bound pref-
erentially by IgE of PS. Quantification of IgE and IgG4 to selected 
peptides using ImmunoCAP technology revealed that specific IgE to 
the Ara h 2 peptides showed very good diagnostic utility and taken 
together with IgE to Ara h 2 were the best serologic marker for pea-
nut allergy and better than Ara h 2-specific IgE alone. Additionally, 
ImmunoCAP allowed precise calculations of IgG4/IgE ratios to indi-
vidual peptides, which were higher in PS than in PA patients, sug-
gesting that the balance of IgG4 and IgE is important in established 
peanut tolerance.
For the first time, we have quantified IgE to peanut peptides 
that were discriminative between allergy and tolerance using 
ImmunoCAP technology and determined the diagnostic value of this 
approach. Importantly, we were able to show that the differences in 
IgE binding to the peptides between PA and PS were independent of 
the level of peanut-specific IgE. The peptides we have identified as 
most discriminative between PA and PS status overlap with some of 
the IgE-binding epitopes previously reported in pioneering studies in 
which IgE binding was assessed using samples from PA patients.14-20 
However, few studies have looked at the comparison of epitope 
specificity between PA and PS patients like ours.21,22 The peptides 
we identified align totally or partially with epitopes reported by Lin 
et al22. Four peptides were particularly important to differentiate PA 
from PS using a machine learning method, decision tree, and support 
vector machine in the latter study22: two peptides on Ara h 2 which 
overlap with two of the peptides we identified and one peptide 
on Ara h 1 and one peptide on Ara h 3, which in turn are different 
from those that we have identified. There are some differences in 
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instance, Lin et al22 used 15-mer peptides with an offset of 3 amino 
acids and only 9% of PS and 13% of PA had IgE to Ara h 1 or Ara h 3 
and 4% of PS and 74% of PA had IgE to Ara h 2; whereas in our study, 
we used 15-mer peptides with an offset of 5 amino acids and the 
majority of patients both from PA and PS groups were sensitized to 
all three major peanut allergens (see Table S4).
We tested for all peanut allergens known at the time of gener-
ation of the microarray. Going beyond testing for the well-studied 
major allergens Ara h 1, Ara h 2, and Ara h 3 enabled us to explore 
the importance of allergens that are not commonly tested for. The 
fact that the peptides that are bound preferentially by IgE of PA than 
by IgE of PS are located on Ara h 1, Ara h 2, and Ara h 3 is a confir-
mation that these major allergens are indeed the most important in 
peanut allergy. More recently, oleosins23 and defensins24 have been 
described in peanut and may also be important; however, IgE to 
these lipophilic allergens is probably not as dominant as IgE to Ara h 
1, Ara h 2, and Ara h 3, given that it is uncommon to find PA patients 
with negative SPT or specific IgE, which are tests that use extracts 
that are defatted and thus lack lipophilic proteins.
The crystal structures of Ara h 1,25,26 Ara h 2,14 and Ara h 327 
have been totally or partially solved; thus, we were able to estab-
lish the location of the relevant peptides in these 3D structures. 
The identified peptides were all located on the surface of peanut 
allergens, in structurally disordered or partially disordered loop re-
gions, accessible to antibody binding. Two Ara h 2 peptides adopt 
a partly alpha-helical conformation in the fusion protein; however, 
in Ara h 2 alone, they might be more flexible. A crystal structure of 
Ara h 2 on its own, without MBP, would be necessary to clarify this. 
Epitopes located on the surface of the allergens are indeed partic-
ularly susceptible to antibody binding, including receptor-bound IgE 
on the membrane of mast cells and basophils, and thus are more 
likely to be able to elicit effector cell activation and allergic symp-
toms. Finding mainly epitopes located on the surface of the aller-
gens could indicate that the linear epitopes were part of epitopes 
formed by parts of the protein that are close in the 3D structure 
but distant in the protein sequence (ie, conformational epitopes). 
Because we used linear short peptides to test for IgE and IgG4 bind-
ing, we will not have been able to detect conformational epitopes. 
Conformational epitopes are likely to be important in IgE binding, 
particularly to allergens that are labile to heating and digestion, such 
as pollen-cross-reactive allergens like Ara h 8 and Ara h 5. In our 
study, a peptide from the peanut profilin Ara h 5 was identified as 
being bound preferentially by IgE of PS than by IgE of PA. Profilins 
are pan-allergens with unclear clinical relevance in peanut allergy.28 
Profilin is likely to be an important cause of false-positives in P-sIgE 
testing, and its importance is probably underestimated as specific 
IgE to peanut profilin is not commercially available and thus is not 
usually tested in isolation. Additional characteristics of IgE, apart 
from epitope specificity, may contribute to the discrepancy between 
sensitization and clinical allergy, notably differences in diversity and 
affinity of IgE antibodies for the peanut epitopes and the spatial dis-
tribution of these epitopes.29
We moved from a semi-quantitative microarray to the quanti-
tative method ImmunoCAP to show the statistical, biological, and 
clinical impact of the epitopes contained in the peptides we identi-
fied. The ImmunoCAP technology allowed us to quantify the levels 
of IgE to the peptides and showed that IgE to the Ara h 2 peptides 
improved the diagnostic utility of IgE to Ara h 2, which could have 
direct practical clinical implications. It was impressive that IgE to Ara 
h 2 peptides alone had good diagnostic performance and could en-
hance the accuracy of Ara h 2-specific IgE, a diagnostic test that is al-
ready able to discriminate very well peanut-allergic from non-allergic 
individuals.3,8 Even if the number of subjects with equivocal levels 
of Ara h 2-specific IgE is a small proportion of the population tested, 
it is clinically relevant for those individuals and could enable us to 
reduce the number of patients we need to subject to an oral pea-
nut challenge. The combination of IgE to the four Ara h 2 peptides 
can improve the diagnostic utility of Ara h 2-specific IgE in equivocal 
cases and, to make this approach more practical, could be provided 
as a single test in the ImmunoCAP platform in the future, following 
additional validation to confirm that such approach would not lead 
to a loss in sensitivity.
The alternative hypothesis we explored related to IgG4 inter-
fering with the interaction between IgE and the allergen. No dif-
ferences in IgG4 binding to peanut peptides could be identified on 
the microarray between PA and PS patients, except for one Ara h 
F I G U R E  2   Peptides indicated on the X-ray structures for (A) Ara h 1 (B) Ara h 2 and (C) Ara h 3. The two overlapping peptides (7 & 8) 
on Ara h 1 are not shown as they are present in a disordered N-terminal region that has been truncated in the crystal structure. The four 
peptides for Ara h 2 are shown as sticks in red (peptides 1 & 3) and blue (overlapping peptides 2 & 4). Only the ordered residues are shown; 
most of these peptide residues are in flexible/disordered loop regions. The peptide for Ara h 3 (peptide 9) is present in the disordered loop 
region of the structure that is indicated by an arrow. The PDB codes for the structures used to generate the figures were as follows: 3S7I (for 
Ara h 1), 3OB4 (for Ara h 2), and 3C3V (for Ara h 3)
2316  |     SANTOS eT Al.
9 peptide. As IgE to Ara h 9 was very low in the studied patients 
and not significantly different between PA and PS patients, the clin-
ical relevance of this finding is unclear. This peptide is predicted to 
adopt an exposed helix and loop structure, based on a model of Ara 
h 9 generated from the highly homologous structure of the pea lipid 
transfer protein (PDB ID: 2N81). Both PA and PS patients tended 
to produce IgE and IgG4 to the same peptides, as reported in a pre-
vious study of Ara h 27; however, the relative amounts of specific 
IgE and IgG4 present were different with IgG4/IgE ratios prevailing 
in PS patients, as we previously showed at the level of the whole 
allergen.2 As the microarray is semi-quantitative, and thus not an 
accurate method to precisely quantify the amount of IgE and IgG4 
antibodies that bound each peptide, we quantified the levels of IgG4 
to the peanut peptides that were distinct between PA and PS in the 
microarray using the ImmunoCAP technology. IgG4/IgE ratios were 
calculated as in previous studies2 and were higher in PS than in PA 
patients for peptides 1, 3, and 4 of Ara h 2 and peptide 9 of Ara h 
3. These findings support the role of the IgG4/IgE balance in estab-
lished peanut tolerance.
Competition for binding to the peptides could potentially have 
interfered with the results of the microarray given that IgE and 
IgG4 binding were measured using the same slide for each patient, 
particularly in the PS group, similar to what occurs in other assays 
using microarrays.30 However, the peptides were printed onto the 
slide in large amounts and in excess of what was expected to be 
bound by IgE; therefore, there should have been enough peptide 
to prevent saturation of the system and to allow enough antibody 
binding. As there was serial exposure to the antibodies used for 
detection of the IgE and the IgG4, controls were included in which 
the detection antibodies were reversed with anti-IgG4 being added 
first followed by anti-IgE; no significant differences were observed. 
Sera from non–peanut-allergic individuals with undetectable pea-
nut-specific IgE and elevated total IgE were additionally used as 
negative controls. Human sera from nonallergic controls and 
chicken sera were also used to check for nonspecific binding.
In the future, we would like to integrate information about the 
exact location of epitopes, the distance between them, and their 
repetition and combination in the allergen structure, with the af-
finity of binding. Understanding the interplay between all these 
F I G U R E  3   Box and violin plots of specific IgE to individual 
peanut peptides and the respective peanut allergen. Peptides 
are grouped and displayed sequentially from left to right overtop 
each of their respective peanut allergen by peanut-allergic (PA), 
peanut-sensitized tolerant (PS) and nonsensitized nonallergic (NA) 
measured by ImmunoCAP (Thermo Fisher). Statistically significant 
comparisons (P < .01) between PA and PS are marked with an * 
above each box plot. The exact P-values are as follows for each IgE 
to the respective peptides and to Ara h1-h3: 1 (<.001), 2 (.543, 3 
(<.001), 4 (.001), 7 (.100, 8 (.280), and 9 (.004), Ara h 1 (<.001), Ara h 
















































































































F I G U R E  4   ROC curves for identifying peanut allergy using 
the following: 1. the combination of IgE to Ara h 2 and IgE to 
each of its peptides (1,2,3,4), labeled “All”; 2. Ara h 2-specific IgE 
alone (labelled "Ara h 2"), and 3. combination of specific IgE to the 
4 Ara h 2 peptides (labeled "Peptides"). The hypothesis test that 
the AUC from all models are equal was rejected (P < .0001), and 
we made the following pair wise comparisons of the difference 
between the AUCs of each model with (95% CI), P-values using 
likelihood-ratio tests. All vs Peptides:.095 (.032,.158), P = .003. 
All vs Ara h2: .028 (.013, .043), P = .0002. Peptides vs Ara h2: 
−.067 (−.138,.004), P = .0656. All data were used for the model 
comparisons, and no imputation of missing data was performed. 
However, because each predictor had different amounts of missing 
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factors could clarify what determines the ability of IgE and allergen 
to cause effector cell activation. Clarifying the mechanism by which 
PS patients do not react to peanut despite the presence of IgE could 
help to identify targets for novel curative treatments for peanut and 
other food allergies.
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F I G U R E  5   IgG4/IgE ratios to individual peptides from (A) Ara h 2 and (B) Ara h 1 and Ara h 3 in peanut-allergic (PA), peanut-sensitized 
tolerant (PS) and nonsensitized nonallergic (NA). IgE and IgG4 levels to the peptides were measured by ImmunoCAP and IgG4/IgE ratios 
were calculated following conversion of IgG4 levels from milligrams per liter to nanograms per milliliter and of IgE levels from kilo unit per 
liter to nanograms per milliliter using the formula log10((IgG4 × 1000)/(IgE × 2.4)). P-values are represented for the comparison across the 
three groups. For the comparison between PA and PS, the P-values are given in brackets for the respective peptides: 1 (<.001), 2 (.9627), 3 
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